Insmed Inc Stock Price, News & Analysis

Insmed (Nasdaq: INSM) held its fourth annual Global Day of Good on November 13, 2025, mobilizing more than 1,200 employees across the U.S., Europe, and Japan for simultaneous volunteer activities.

Teams supported health, education, and human services through meal-packing, care packages for children with serious diseases, STEM and hygiene kits, book translation, and outdoor space restoration. The company offers year-round volunteer programs, matching gifts, and paid volunteer time.

Insmed (Nasdaq: INSM) announced management will present at two investor conferences in November and December 2025: the Jefferies Global Healthcare Conference in London on Tuesday, November 18, 2025 at 8:30 a.m. GT / 3:30 a.m. ET, and the Evercore 8th Annual Healthcare Conference in Coral Gables, Florida on Tuesday, December 2, 2025 at 11:15 a.m. ET.

Both presentations will be webcast live and archived for 30 days on Insmed's investor relations website at www.insmed.com.

Insmed (Nasdaq: INSM) reported third-quarter 2025 results and a business update on October 30, 2025. Total revenue was $142.3 million in Q3 2025, driven by ARIKAYCE $114.3M (+22% YoY) and BRINSUPRI $28.1M following FDA approval and U.S. launch. The company raised full-year ARIKAYCE guidance to $420M–$430M (15%–18% YoY growth).

R&D and SG&A each were $186.4M in Q3, and Insmed reported a net loss of $370.0M (−$1.75/share). Cash and marketable securities totaled about $1.7B as of Sept 30, 2025. Key clinical catalysts are expected through 2026 across ARIKAYCE, brensocatib, and TPIP programs.

Insmed (Nasdaq: INSM) ranked No. 1 on Science's 2025 Top Biopharma Employers list, marking a record fifth consecutive year at the top, announced Oct. 23, 2025. The ranking is based on about 5,500 survey responses, primarily from North America (66%), Europe (20%), and Asia/Pacific Rim (9%). The company linked the recognition to a people-first culture and cited recent clinical successes and regulatory milestones as drivers of growth. Insmed highlighted strengths in corporate image, financial prowess, leadership, work culture, and intellectual challenge. More details and rankings are available on the publisher's feature and Insmed's culture page.

Insmed (Nasdaq: INSM) announced that the EMA Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on BRINSUPRI (brensocatib 25 mg) on October 17, 2025, recommending approval for treatment of non-cystic fibrosis bronchiectasis (NCFB) in patients aged 12 years and older with two or more exacerbations in the prior 12 months.

BRINSUPRI was reviewed under the CHMP's accelerated assessment and had prior PRIME designation; the opinion is based on Phase 3 ASPEN and Phase 2 WILLOW data published in the New England Journal of Medicine. The European Commission will issue a final decision in the coming months.

Insmed (Nasdaq: INSM) will present six abstracts from the Phase 3 ASPEN trial of BRINSUPRI (brensocatib) at CHEST 2025 in Chicago, Oct 19–22, 2025. Presentations include prespecified and post‑hoc subgroup analyses, a late‑breaking high‑resolution CT substudy on structural lung changes, NSP (neutrophil serine protease) suppression data, and analyses of efficacy, symptom burden, and biomarker effects in patients with non‑cystic fibrosis bronchiectasis (NCFB).

Sessions cover COPD comorbidity, Asian population outcomes, BEST symptom assessments during and outside exacerbations, and multiple poster and oral presentations led by named investigators across Oct 20–22, 2025.

Insmed (Nasdaq: INSM) will release its third-quarter 2025 financial results on Thursday, October 30, 2025. Management will host a conference call for investors at 8:00 a.m. ET the same day to discuss results and provide a business update.

Investors may dial (888) 210-2654 (U.S.) or (646) 960-0278 (international) using access code 7862189, or listen via live webcast at www.insmed.com. A replay will be available about one hour after the call through November 6, 2025 by dialing (800) 770-2030 (U.S.) or (609) 800-9909 (international) with access code 7862189. The webcast will be archived for 90 days under the Investor Relations section of the company website.

Insmed (NASDAQ:INSM) will present seven abstracts from its late-stage portfolio at the European Respiratory Society (ERS) 2025 Congress from September 27 to October 1, 2025, in Amsterdam.

A key highlight includes data from the Phase 2b TPIP trial in pulmonary arterial hypertension patients, which will be featured in the prestigious ALERT session for late-breaking clinical data. Additionally, the company will present three prespecified subgroup analyses from the Phase 3 ASPEN trial evaluating brensocatib, including Japanese patient data, and Health Outcomes Research from the THIN database focusing on non-cystic fibrosis bronchiectasis (NCFB) patients in France and the UK.

The presentations will take place across multiple sessions, including oral presentations and poster sessions, showcasing various aspects of their clinical research and patient outcomes.

Insmed (Nasdaq: INSM) has granted inducement awards to 115 new employees under its 2025 Inducement Plan, complying with Nasdaq Listing Rule 5635(c)(4). The grants, approved on August 29, 2025, include 70,742 restricted stock units and options to purchase 8,420 shares at $136.10 per share.

The restricted stock units feature a four-year vesting schedule with 25% vesting annually. The stock options have a 10-year term with 25% vesting after the first year and 12.5% vesting semi-annually for the following three years, subject to continued employment.